Clinical Trial Update: Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease [Phase 3]

View source ↗

Summary

Phase 3 results report on the efficacy and safety of rivastigmine transdermal patch in patients with mild to moderate Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Exelon Patch (rivastigmine transdermal patch)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Alzheimer's Disease | Phase 3 | Status: COMPLETED | Results posted: 2011-05-25